Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. EuropeanOrganization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
2. Food and Drug Administration Oncologic Drugs Advisory Committee, April 27-29, 2021. https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-27-29-2021-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04272021-04292021#event-materials. Accessed October 27, 2022.
3. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer. 2006;6:409–14.
4. Claret L, Girard P, O’Shaughnessy J, Hoff P, Van Cutsem E, Blum J, et al. Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. J Clin Oncol. 2006;24:6025–6025.
5. Gong Y, Mason J, Shen YL, Chang E, Kazandjian D, Blumenthal GM, et al. An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2020;38:9541–9541.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献